GlyCardial Diagnostics

Our mission is to improve the early diagnosis
of cardiac ischemic events to reduce
the impact of the disease on patients' life

GlyCardial Diagnostics is developing Apo J-Glyc as a novel biomarker for the diagnosis and prognosis of myocardial ischemia

Acute ischemic events are still one of the most common cardiac emergencies with substantial morbidity and mortality worldwide. Early detection of ischemia is essential to prevent irreversible myocardial damage and heart failure. Therefore, there is an unmet medical need to detect ischemia independently of the presence of necrosis

Latest News

Be the first to read